Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Darbepoetin Alfa Extended Dosing

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than or equal to 18 years of age~* CRI with a creatinine clearance of greater than 15 but less than 40 mL/min~* Stable once every other week darbepoetin alfa SC for at least 6 weeks~* Hb values during screening / baseline of 10.0 - 12.0 g/dL~* Serum B12 and folate levels above the lower limit of normal and iron replete~Exclusion Criteria:~* Receiving renal replacement therapy~* Uncontrolled hypertension~* Hyperparathyroidism~* Major surgery, active inflammatory disease, receiving antibiotics, HIV-positive~* Current malignancy~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- darbepoetin alfa (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).